Fast Five Quiz: How Much Do You Know About HIV?

Michael Stuart Bronze, MD; Nicholas J. Bennett, MBBCh, PhD, MA(Cantab)

Disclosures

May 10, 2021

According to the HHS guidelines, an ARV regimen for a treatment-naive patient generally consists of a dual NRTI regimen administered in combination with a third active ARV drug from one of three drug classes: an INSTI, a NNRTI, or a PI with a PK enhancer. The use of the INSTI dolutegravir, plus the NRTI lamivudine, is also recommended in certain patient populations (see below). Recommended initial regimens include:

  • Bictegravir/tenofovir alafenamide/emtricitabine

  • Dolutegravir/abacavir/lamivudine — only for individuals who are HLA-B*5701 negative and without chronic hepatitis B virus (HBV) coinfection

  • Dolutegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide or tenofovir disoproxil fumarate)

  • Dolutegravir/lamivudine — except for individuals with HIV RNA > 500,000 copies/mL, HBV co-infection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available

  • Raltegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF])

For additional information, refer to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.

Learn more about HIV treatment approaches.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....